Clinical pharmacokinetics and pharmacodynamics of selegiline: An update

Clinical Pharmacokinetics

Volumn 33, Issue 2, 1997, Pages 91-102

  Mahmood, Iftekhar ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DRUG METABOLITE; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE;

DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030832391     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199733020-00002     Document Type: Review

References (44)

1. Knoll J, Ecscri Z, Kelemen K, et al. Phenylisopropylmethyl propinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn 1965; 155: 154-64
2. Tipton KF, Fowler CJ. Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press. 1984
3. Knoll J. Deprenyl facilitates the activity of the nigrostrialal dopaminergic neuron. J Neural Transm 1987: 25 Suppl.: 45-66
4. Bentué-Ferrcr D, Menard G, Allain H. Monoamine oxidase B inhibitors: current status and future potential. CNS Drugs 1996; 6: 217-36
5. Juvanez Z, Rotonyi I, Toth A, et al. Chromatographic determination of nanogram levels of 2-(methylpropargylamino)-l-phenylpropane (Jumex, Deprenyl) in plasma. J Chromatogr 1984; 286: 363-9
6. Patrick K, Nguyen B, McCallister J, Gas chromatographicmass spectrometric determination of plasma selegiline using a deuteraled internal standard. J Chromatogr 1992; 583: 254-8
7. Mahmood I.,Neau SH, Mason WD. An enzymatic assay for the analysis of sclegiline in plasma. J Pharm Biomed Anal 1994; 12: 895-9
8. Michaelis K, Waitainger J, Agavaz U, et al. Pharmacokinetics of L-deprenyl and N-desmethylselegiline in blood versus plasma after single oral administration of I 10mg selegiline. Pharm Res 1993; 10 Suppl.: 331
9. Lessard D, Menabo W, Menard C, et al. Determination of selegiline and desmethylselegiline in human plasma by GC with mass selective detection, Pharm Res 1993; 10 Suppl.: 52
10. Barrett JS, Rohatagi S, Dewwitt KE, et al. The effect of dosing regimen and food on the bioavailability of the extensively metuholiy.cd. highly variable drug eldepryl (selegiline hydrochloride). Am J Ther 1996; 3: 298-313
11. Barren JS, Hochadel TJ, Momies RJ, et al. Pharmaenkinetics and safety of selegiline transdermal system relative to single dose oral administration in the elderly. Am J Ther 1996; 3: 1-11
12. Mahmood I, Marinae JS, Willsie S, et al. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm Drug Disp 1995; 16: 535-45
13. Heinonen EH, Anttila M, Karnani H, et al. Pharmacokinetic of selegiline after oral dosing [abstract]. Men Disord 1994; 9 Suppl.: 57
14. Mahmood I, Peters DK, Mason WD. The pharmacokinetics and absolute bioavailability of selegiline in the dog. Biopharm Drug Disp 1994; 15: 653-64
15. Murley E, Blackwell B. Interaction of momumine osidase inhibitors, amines and food stuffs. Adv Pharmacol Chemother 1970; 8: 186-239
16. Elsworth JD, Glover V, Reynold GP, et al, Deprenyl administration in man: a selective monoamine oxidase B inhibitors without the 'cheese effect'. Psychopharmacology 1978; 57: 33-8
17. Gaudreault J, Wang S, Lalonde R. Selegilinc population pharmacokinetics. Pharm Res 1994; II Suppl.: 327
18. Rohalagi S, Barrett JS, Dewwitt KE, et al. Multiple dode pharmacokinetics and dose proportionality of selegiline and metabolites in healthy males following transdermal administration, Pharm Res 1996: 13 Suppl.: 502
19. Dostert P, Streilin-Benedetti M. Persiani S, et al. Luck of pharmucokinetic interaction between the selective dopaminie agonist cabergolinc and the MAO-B inhibitor selegiline. J Neural Transm Suppl 1995; 45: 247-57
20. Dingemanse J, Kneer J, Wallnofer A, et al. Pharmacokinetic-pharmacodynamic interaction between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol 1996; 19: 399-414
21. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Purkinson's disease. Drugs Aging 1991; 3: 228-48
22. Yoshida T, Yamuada Y, Yamamoto T, et al. Metabolism of deprenyl, a selective monoaminc oxidase (MAO) B inhibitor in rat: relationship of metabolism in MAO-B. Xenohiotic 1986; 16: 129-39
23. Yamlahi L, Besner JG, Caille G, Pharmacokinetics and its major metabolite N-desmethylselegiline after intravenous and inlraduodenal administration of selegilino in dog. Pharm Res 1993; 10 Suppl.: 336
24. Grace CM, Kinter MT, Macdonald TL. Atypical metabolism of deprenyl and its enunlinmcr, (S)-(+)-N,a-dimethyl-N-propynlphenethylamine. by cytochrome P4502D6. Chem Res Toxicol 1994; 7: 286-90
25. Rohutugi S, Barren JS, McDonald LJ, et al. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm Res 1997; 14: 50-5
26. Fowler CI, O'Carroll A, Tipton KF. Domination of dopamine hy monoumine oxidase A and B in rat and in Man. In: Tipton KF, Dosiert P, Slrolin Benedetti M, editors. Monoamine oxidase and disease. London: Academic Press. 1984
27. Donnelly CH, Murphy DL. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochcm Pharmacol 1977; 26: 853-8
28. Sonsala PK, Golbe LI, Deprenyl as prophylaxis against Parkinson's disease? Clin Neuropharmacol 1988; 11: 500-11
29. Glover V, Sandier M, Owen F, et al. Dopamine is a monoamine oxidase B substrale in man. Nature 1977; 265: 80-1
30. Morinan A, Garrat H, An improved fllurometric assay for brain monoamine oxidase. J Pharmacol Methods 1988; 13: 213-23
31. Fowler CJ, Tipton KF. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J Neurochem 1982; 38: 733-6
32. Lichowitz MR, Karroum F, Quitkin FM, et al. Biochemical effects of L-deprenyl in atypical depressives. Biol Psychiatry 1985; 20: 558-65
33. Benedetti MS, Sontag N, Boucher T, et al. Function and regulation of monoamine enzymes: basic and clinical aspects. London: Macmillan, 1984
34. Kalir A, Sabbagh A, Youdim MBH, Selective acetylinic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 1981; 73: 55-64
35. Parada MD, Cesura AM, Launay JM, et al. Platelets as a model for neurons. Experienlia 1988; 44: 115-26
36. Lee DH, Mendoza M, Dvorozniak MT, et al. Platelet monoamine osidase in Parkinson patients: effect of L-deprenyl therapy. J Neural Transm 1989; 1: 189-94
37. Simpson GM, Frederickson F., Palmer R, et al. Platelet monoumine oxidase inhibition by deprenyl and trunyleypromine: implications for clinical use. Biol Psychiatry 1985; 20: 680-4
38. Heinonen E, Antilla M, Lammintausta K. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolism. Clin Pharmucol Ther 1994; 56: 742-9
39. Heinonen li, L ammintuusta R. A review of the pharmacology of selegiline. Acta Nourol Stand 1991; 84 Suppl. 136: 44-59
40. Sunderland T, Tarint PN, Cohen RM, et al. Dose dependent effects of deprenyl on CSF monouminc metubolism in patients with Alzheimer's disease. Psychopharmacology 1987; 91: 293-6
41. Riederer H, Youdim MBH. Monoamine oxidase activity und monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl. J Neurochem 1989; 52: 515-20
42. Heinonen EH, Anttila M, Nynuin L, et al. Desmethylsclcgiline, a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects. Neurology 1993; 43 Suppl.: A156
43. Borbe H, Niehch G, Nickel B. Kinetic evaluation of MAO-B activity following oral administration of selegiline and dusmethylselegiline in the rat. J Neural Transm 1990; 32 Suppl.: 131-7
44. Heinonen EH, Selegiline in the treatment of Purkinson's disease: pharmacokinetic and clinical studies [dissertation]. Turku (Finland): University of Turku. 1995